Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid in reverse total shoulder arthroplasty
NCT02043132Phase 3Completed
- Sponsor
- Corewell Health
- Start
- Sep 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tranexamic acid in hemorrhage (2 arms), sponsored by Corewell Health. Primary endpoints: Total Blood Loss at 48 hours, Total Hemoglobin Loss at 48 hours and 1 more. Started Sep 2013; status: completed.
02
Drugs
tranexamic acid
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT02043132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043132.